Proactive Investors - Run By Investors For Investors

LexaGene hits major milestone, places its pathogen-detecting technology in major Massachusetts veterinary hospital

The beta prototype identifies the presence of bacteria causing urinary tract infections in animals and screens samples for common antibiotic resistance factors so vets can make treatment decisions
dog and cat
The prototype was placed at Massachusetts Veterinary Referral Hospital, part of a US-wide network

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Wednesday that a major veterinary hospital in Massachusetts will house the first beta prototype of the company’s LX Analyzer.

The beta prototype identifies the presence of bacteria causing urinary tract infections in animals and screens samples for common antibiotic resistance factors so that veterinarians have the correct information to select the best course of treatment.

LexaGene's shares jumped 9.5% at C$0.69 in Toronto on Wednesday morning and 15.3% at US$0.52 on OTC markets.

READ: LexaGene Holdings completes development of antibiotic resistance marker panel

Massachusetts-based LexaGene said the prototype had been placed at Massachusetts Veterinary Referral Hospital, which is among 24 hospitals owned by Ethos Veterinary Health, a US network of veterinary hospitals providing specialty and emergency care for pets.

“This placement marks a very significant milestone for the company and for the diagnostics industry,” said Dr Jack Regan, LexaGene’s founder and CEO.

According to Regan, the company selected Mass Vet to be its first site due to their reputation for being pioneers and thought leaders in veterinary medicine. “The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” he said.

LexaGene said it will continue placing devices at various other sites throughout the US as part of an ongoing beta test program.

“This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods,” Regan said in a statement. “We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

Key features

LexaGene is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis.

The key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The instrument is able to process multiple samples at a time, returning results within around one hour.

In addition to veterinary health, LexaGene is initially targeting the food safety industry to detect potential crop-killing pathogens.

--Updates share price--

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full LXG profile View Profile

Lexagene Holdings Inc Timeline

Related Articles

woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use